Childhood asthma: Balancing efficacy and adherence for optimum management

Postgraduate Medicine

Volumn 118, Issue 3, 2005, Pages 43-50

  Sveum, Richard J ^a,b  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b PARK NICOLLET CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; CROMOGLYCATE DISODIUM; FLUTICASONE; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MONTELUKAST; SALMETEROL XINAFOATE; THEOPHYLLINE; ZAFIRLUKAST; ZILEUTON; ACETIC ACID DERIVATIVE; ANTIASTHMATIC AGENT; QUINOLINE DERIVATIVE; TOLUENESULFONIC ACID DERIVATIVE;

ASTHMA; CELLULAR IMMUNITY; CHILD; CHILDHOOD DISEASE; DOSE RESPONSE; FORCED EXPIRATORY VOLUME; HUMAN; INCIDENCE; MEDICAL PRACTICE; PATIENT COMPLIANCE; PEAK EXPIRATORY FLOW; REVIEW; SIDE EFFECT; UNITED STATES; ADOLESCENT; ADULT; HOSPITALIZATION; INFANT; PRACTICE GUIDELINE; PRESCHOOL CHILD;

ACETATES; ADOLESCENT; ADULT; ANTI-ASTHMATIC AGENTS; ASTHMA; CHILD; CHILD, PRESCHOOL; HUMANS; INFANT; LEUKOTRIENE ANTAGONISTS; PRACTICE GUIDELINES; QUINOLINES; SEVERITY OF ILLNESS INDEX; TOSYL COMPOUNDS;

EID: 26944443147     PISSN: 00325481     EISSN: 12182583     Source Type: Journal    
DOI: 10.3810/pgm.2005.09.1709     Document Type: Review

References (23)

1. National Asthma Education and Prevention Program. Expert panel report: guidelines for the diagnosis and management of asthma. Update on selected topics - 2002. J Allergy Clin Immunol 2002;110(5 Suppl):S141-219
2. Knorr B, Matz J, Bernstein JA, et al. Montelukast for chronic asthma in 6- to 14-year-old children: a randomized, double-blind trial. Pediatric Montelukast Study Group. JAMA 1998;279(15):1181-6
3. Knorr B, Franchi LM, Bisgaard H, et al. Montelukast, a leukotriene receptor antagonist, for the treatment of persistent asthma in children aged 2 to 5 years. Pediatrics 2001;108(3):E48
4. Pearlman DS, Lampl KL, Dowling PJ Jr, et al. Effectiveness and tolerability of zafirlukast for the treatment of asthma in children. Clin Ther 2000;22(6):732-47
5. Bisgaard H. Leukotriene modifiers in pediatric asthma management. Pediatrics 2001;107(2):381-90
6. Knorr B, Noonan G, Nguyen H, et al. Evaluation of the safety profile of montelukast (MK-0476) in pediatric patients aged 2 to 5 years. (Abstr) J Allergy Clin Immunol 2000;105(1 part 2):524
7. 4-receptor antagonist zafirlukast attenuates exercise-induced bronchoconstriction in children. J Pediatr 1999;134(3):273-9
8. Accolate package insert. Wilmington, Del: Zeneca Pharmaceuticals, 1999
9. Simons FE, Villa JR, Lee BW, et al. Montelukast added to budesonide in children with persistent asthma: a randomized, double-blind, crossover study. J Pediatr 2001;138(5):694-8
10. Leff JA, Busse WW, Pearlman D, et al. Montelukast, a leukotriene-receptor antagonist, for the treatment of mild asthma and exercise-induced bronchoconstriction. N Engl J Med 1998;339(3):147-52
11. Kemp JP, Dockhorn RJ, Shapiro GG, et al. Montelukast once daily inhibits exercise-induced bronchoconstriction in 6- to 14-year-old children with asthma. J Pediatr 1998;133(3):424-8
12. Bisgaard H, Loland L, Anhoj J. NO in exhaled air of asthmatic children is reduced by the leukotriene receptor antagonist montelukast. Am J Respir Crit Care Med 1999;160(4):1227-31
13. Ghiro L, Zanconato S, Rampon O, et al. Effect of montelukast added to inhaled corticosteroids on fractional exhaled nitric oxide in asthmatic children. Eur Respir J 2002;20(3):630-4
14. van Adelsberg J, Wei LX, Knorr B, et al. Safety and tolerability of montelukast (sprinkles) in 6- to 24-month old asthmatic patients. (Abstr) Am J Respir Crit Care Med 2002;165:A744
15. van Adelsberg J, Montalvo J, Liu N, et al. Safety and tolerability of montelukast, a leukotriene receptor antagonist, in >6- to <31-month-old asthmatic patients: evaluation at 3 months. (Abstr) Am J Respir Crit Care Med 2003;167:A271
16. Migoya E, Kearns GL, Hartford A, et al. Pharmacokinetics of montelukast in asthmatic patients 6 to 24 months old. J Clin Pharmacol 2004;44(5):487-94
17. Maspero JF, Duenas-Meza E, Volovitz B, et al. Oral montelukast versus inhaled beclomethasone in 6- to 11-year-old children with asthma: results of an open-label extension study evaluating long-term safety, satisfaction, and adherence with therapy. Curr Med Res Opin 2001;17(2):96-104
18. Jones C, Santanello NC, Boccuzzi SJ, et al. Adherence to prescribed treatment for asthma: evidence from pharmacy benefits data. J Asthma 2003;40(1):93-101
19. Williams B, Noonan G, Reiss TF, et al. Long-term asthma control with oral montelukast and inhaled beclomethasone for adults and children 6 years and older. Clin Exp Allergy 2001;31(6):845-54
20. Bukstein DA, Luskin AT, Bernstein A. "Real-world" effectiveness of daily controller medicine in children with mild persistent asthma. Ann Allergy Asthma Immunol 2003;90(5):543-9
21. [Erratum, Ann Allergy Asthma Immunol 2003;91(3):308]
22. Weinberg EG, Naya I. Treatment preferences of adolescent patients with asthma. Pediatr Allergy Immunol 2000;11(1):49-55
23. Szefler SJ, Phillips JR, Martinez FD, et al. Characterization of within-subject responses to fluticasone and montelukast in childhood asthma. J Allergy Clin Immunol 2005;115(2):232-42